Weight Loss

European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
Eli Lilly's $6 Billion Alabama Site To Make Next-Gen Weight Loss Pills
Eli Lilly's $6 Billion Alabama Site To Make Next-Gen Weight Loss Pills
Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat
Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat

Weight Loss Recent News

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 mg option.
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 phase 3 launch.
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share.
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.
Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion
Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion
Eli Lilly plans over $1 billion investment in India to expand drug manufacturing, partnerships, and a new Hyderabad facility.
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
Roche Targets Top Spot In Weight Loss Drug Market
Roche Targets Top Spot In Weight Loss Drug Market
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.
Could This New Drug Be The Safer Way To Fight Obesity?
Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's (NYSE:UNH) rebound. Clinical wins, upgrades, and a more forgiving valuation could result in a potential rebound for NVO stock.
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved